Xylocor
Malvern, US · Delaware corporation · 5 known investors
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Founders & leadership
RC
Ronald CrystalCo-founder
TR
Todd RosengartCo-founder
JT
John TuckerPresident and Chief Executive Officer
AG
Albert GianchettiExecutive
Board
GB
Glenn BatchelderBoard director
JC
James CohenBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$21.4M disclosed across 6 of 7 rounds · 2016–2025
▶$4MraisedJan 2021 · 5 investors · BiotechnologyRule 506(b)
▶$4MraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fouad Azzam, Ph.D.Director
- Aidan KingDirector
- Michael F. Powell, Ph.D.Director
- Todd K. Rosengart, M.D.Director
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- Amount sold
- $4M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedOct 2018 · 7 investors · BiotechnologyRule 506(b)
▶$16.8MraisedOct 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd RosengartDirector
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- James CohenDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Glenn BatchelderDirector
- James CohenDirector
- Todd RosengartDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$60KraisedMar 2018 · 4 investors · BiotechnologyRule 506(b)
▶$60KraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James CohenDirector
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- Todd RosengartDirector
- Offering amount
- $150K
- Amount sold
- $60K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$100KraisedDec 2017 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedDec 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd RosengartDirector
- Glenn BatchelderDirector
- James CohenDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$250KraisedNov 2016 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedNov 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Glenn BatchelderDirector
- James CohenDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapCapricor15 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
CeleCor Therapeutics13 shared keywordsCeleCor Therapeutics is developing zalunfiban, an investigational next-generation GPIIb/IIIa platelet inhibitor injected subcutaneously for the pre-hospital treatment of STEMI heart attacks at the first point of medical contact. The company focuses on improving acute myocardial infarction treatment.
Arecor12 shared keywordsArecor develops proprietary therapeutics for diabetes and other cardiometabolic diseases using its Arestat formulation and drug delivery technology platform. It also partners with pharmaceutical and medtech companies to improve therapeutic profiles.
DalCor www.dalcorpharma.com7 shared keywordsDalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
AliveCor6 shared keywordsAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.
Companies competing with Xylocor for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Xylocor do?
- XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
- Who founded Xylocor?
- Xylocor was founded by Ronald Crystal, Todd Rosengart.
- Who are Xylocor's investors?
- Xylocor's investors include Lumira Ventures, Fountain Healthcare Partners, Jeito Capital, Longwood Fund, Sofinnova Ventures.
- How much funding has Xylocor raised?
- Xylocor has disclosed $21.4M raised across 6 of its 7 known rounds.
- Where is Xylocor headquartered?
- Xylocor is headquartered in Malvern, US.